Bulletin: Florida Gas Utility's $694M Bonds Unaffected By The Downgrade Of Dexia Bank S.A. Oct 08

  • ID: 1856441
  • October 2008
  • Region: Florida
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Oct. 8, 2008--Standard & Poor's Ratings Services said today that the downgrade of Dexia Bank S.A. (A+/Watch Dev/A-1) does not affect the rating or outlook on Florida Gas Utility's (FGU) series 2006A bonds (AA-/A-1+/Negative). The downgrade of Dexia reflects the negative impact that current turbulent market conditions are having on its financial profile, mainly in terms of revenues and access to funding, and our view that Dexia's recent difficulties have also weakened the group's business franchise. The rating on the prepay transaction is tied to the rating on FGU's gas supplier, UBS AG (AA-/Negative/A-1+). Standard & Poor's could lower the rating on FGU's transaction if it lowers the rating on UBS. Dexia, Calyon (AA-/Stable/A-1+), and...

Companies mentioned in this report are:
- Belfius Bank SA/NV

Action: Bulletin

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Belfius Bank SA/NV

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.